Literature DB >> 1568463

Effects of interleukin 3 and interleukin 6 on platelet recovery in mice treated with 5-fluorouracil.

P A Carrington1, R J Hill, J Levin, D Verotta.   

Abstract

We have studied the effects of murine recombinant interleukin 3 (IL-3) and human recombinant interleukin 6 (IL-6) on platelet recovery after administration of 5-fluorouracil (5-FU) to mice. 5-FU at 250 mg/kg body weight was administered as a single i.p. injection, and treatment with IL-3 alone, IL-6 alone, or a combination of IL-3 plus IL-6 was initiated immediately following the 5-FU or after a delay of 2 days. In addition, the effects of the combination of IL-3 plus IL-6 were evaluated following delays in initiation of their administration until 4 or 6 days after 5-FU treatment. In all schedules, the IL-3 and IL-6 treatments were discontinued 8 days following 5-FU. IL-3 and IL-6 were given s.c. three times daily; each injection of IL-3 was 80,000 U, each injection of IL-6 was 5000 U, and the combination comprised separate injections of IL-3 and IL-6 at the same respective doses. The combination of IL-3 and IL-6, initiated immediately or 2 days following 5-FU, diminished the platelet nadir and increased platelet counts on individual days during the recovery phase, thus apparently decreasing the time required for recovery to a normal platelet level. However, using self-modeling nonlinear regression, in order to analyze variability in the duration of thrombocytopenia, statistically significant shortening of the period of thrombocytopenia could not be consistently demonstrated. Neither IL-3 alone nor IL-6 alone had any effect on the above parameters. Recovery of hematocrit values and white blood cell levels was unaffected by administration of either IL-3 or IL-6 alone or the combination of both cytokines. We propose that IL-3 and IL-6 can act synergistically to enhance platelet recovery following 5-FU-mediated thrombocytopenia, but their modification of the response to 5-FU is modest.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1568463

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  2 in total

1.  Effective prevention of thrombocytopenia in mice using adenovirus-mediated transfer of HST-1 (FGF-4) gene.

Authors:  H Konishi; T Ochiya; H Sakamoto; M Tsukamoto; I Saito; T Muto; T Sugimura; M Terada
Journal:  J Clin Invest       Date:  1995-08       Impact factor: 14.808

2.  Toll-like receptor-5 agonist Entolimod broadens the therapeutic window of 5-fluorouracil by reducing its toxicity to normal tissues in mice.

Authors:  Bojidar M Kojouharov; Craig M Brackett; Jean M Veith; Christopher P Johnson; Ilya I Gitlin; Ilia A Toshkov; Anatoli S Gleiberman; Andrei V Gudkov; Lyudmila G Burdelya
Journal:  Oncotarget       Date:  2014-02-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.